{"id":744319,"date":"2023-03-31T09:58:09","date_gmt":"2023-03-31T13:58:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/"},"modified":"2023-03-31T09:58:09","modified_gmt":"2023-03-31T13:58:09","slug":"tekla-life-sciences-investors-paid-distribution-11","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/","title":{"rendered":"Tekla Life Sciences Investors Paid Distribution"},"content":{"rendered":"

<\/p>\n

Tekla Life Sciences Investors Paid Distribution<\/b><\/p>\n

BOSTON–(BUSINESS WIRE<\/a>)–
\nOn March 31, 2023, Tekla Life Sciences Investors paid a distribution of $0.33 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $39,622,658, of which $31,823,721 represents net unrealized appreciation of portfolio securities.\n<\/p>\n

\nThe following table sets forth the estimated amounts of the current distribution, paid on March 31, 2023, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that you have invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund\u2019s investment performance and should not be confused with \u2018yield\u2019 or \u2018income\u2019. All amounts are expressed per common share.\n<\/p>\n\n\n\n\n\n\n\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

Current Distribution<\/b><\/p>\n<\/td>\n

\n

Percentage Breakdown of Current Distribution<\/b><\/p>\n<\/td>\n

\n

Total Cumulative Distributions for the Fiscal Year to Date1<\/sup><\/b><\/p>\n<\/td>\n

\n

Percentage Breakdown of the Total Cumulative Distributions for the Fiscal Year to Date1<\/sup><\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nNet Investment Income\n<\/p>\n<\/td>\n

\n

\n$0.0000\n<\/p>\n<\/td>\n

\n

\n0%\n<\/p>\n<\/td>\n

\n

\n$0.0000\n<\/p>\n<\/td>\n

\n

\n0%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet Realized ST Cap Gains\n<\/p>\n<\/td>\n

\n

\n$0.0000\n<\/p>\n<\/td>\n

\n

\n0%\n<\/p>\n<\/td>\n

\n

\n$0.0000\n<\/p>\n<\/td>\n

\n

\n0%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet Realized LT Cap Gains\n<\/p>\n<\/td>\n

\n

\n$0.0000\n<\/p>\n<\/td>\n

\n

\n0%\n<\/p>\n<\/td>\n

\n

\n$0.0000\n<\/p>\n<\/td>\n

\n

\n0%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nReturn of Capital or Other Capital Source\n<\/p>\n<\/td>\n

\n

\n$0.3300\n<\/p>\n<\/td>\n

\n

\n100%\n<\/p>\n<\/td>\n

\n

\n$0.6400\n<\/p>\n<\/td>\n

\n

\n100%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTOTAL (per common share):\n<\/p>\n<\/td>\n

\n

\n$0.3300\n<\/p>\n<\/td>\n

\n

\n100%\n<\/p>\n<\/td>\n

\n

\n$0.6400\n<\/p>\n<\/td>\n

\n

\n100%\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nThe table below includes information relating to the Fund\u2019s performance based on its NAV for certain periods.\n<\/p>\n\n\n\n\n\n
\n

\nAverage annual return at NAV for the period from January 31, 2018 through January 31, 2023\n<\/p>\n<\/td>\n

\n

\n4.25\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAnnualized current distribution rate expressed as percentage of NAV as of January 31, 2023\n<\/p>\n<\/td>\n

\n

\n7.78\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCumulative total return at NAV for the fiscal year, through January 31, 20232<\/sup><\/p>\n<\/td>\n

\n

\n11.74\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of January 31, 20231<\/sup><\/p>\n<\/td>\n

\n

\n3.77\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nYou should not draw any conclusions about the Fund\u2019s investment performance from the amount of this distribution or from the terms of the Fund\u2019s managed distribution policy.\n<\/p>\n

\nThe amounts and sources of distributions reported in this press release are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund\u2019s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.\n<\/p>\n

\nTekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests in companies in the healthcare industry.\n<\/p>\n

\nTekla Capital Management LLC, the Fund\u2019s investment adviser, is a Boston, MA based healthcare-focused investment manager with approximately $3.2 billion of net assets under management as of December 31, 2022. Tekla also serves as investment adviser to Tekla Healthcare Investors (NYSE: HQH), Tekla Healthcare Opportunities Fund (NYSE: THQ) and Tekla World Healthcare Fund (NYSE: THW), closed-end funds that invest in companies in the healthcare and life sciences industries. Information regarding the Funds and Tekla Capital Management LLC can be found at www.teklacap.com<\/a>.\n<\/p>\n

\nPlease contact Destra Capital Advisors, the Fund\u2019s marketing and investor support services agent, at HQL@destracapital.com<\/a> or call (877) 855-3434 if you have any questions regarding HQL.\n<\/p>\n\n\n\n
\n

\n(1)\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nThe Fund\u2019s current fiscal year began on October 1, 2022.\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(2)\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nCumulative total return at NAV is the percentage change in the Fund\u2019s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2022 through January 31, 2023.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u00a0\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230331005308\/en\/<\/a><\/span><\/p>\n

\nDestra Capital Advisors
\n
HQL@destracapital.com
\n<\/a>
(877) 855-3434\n<\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Banking Professional Services Finance<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Tekla Life Sciences Investors Paid Distribution BOSTON–(BUSINESS WIRE)– On March 31, 2023, Tekla Life Sciences Investors paid a distribution of $0.33 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $39,622,658, of which $31,823,721 represents net unrealized appreciation of portfolio securities. The following table sets forth the estimated amounts of the current distribution, paid on March 31, 2023, and the cumulative distributions paid this … <\/p>\n

Continue reading “Tekla Life Sciences Investors Paid Distribution”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-744319","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTekla Life Sciences Investors Paid Distribution - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tekla Life Sciences Investors Paid Distribution - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Tekla Life Sciences Investors Paid Distribution BOSTON–(BUSINESS WIRE)– On March 31, 2023, Tekla Life Sciences Investors paid a distribution of $0.33 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $39,622,658, of which $31,823,721 represents net unrealized appreciation of portfolio securities. The following table sets forth the estimated amounts of the current distribution, paid on March 31, 2023, and the cumulative distributions paid this … Continue reading "Tekla Life Sciences Investors Paid Distribution"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-31T13:58:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tekla Life Sciences Investors Paid Distribution\",\"datePublished\":\"2023-03-31T13:58:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/\"},\"wordCount\":669,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/\",\"name\":\"Tekla Life Sciences Investors Paid Distribution - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-03-31T13:58:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tekla-life-sciences-investors-paid-distribution-11\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tekla Life Sciences Investors Paid Distribution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tekla Life Sciences Investors Paid Distribution - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/","og_locale":"en_US","og_type":"article","og_title":"Tekla Life Sciences Investors Paid Distribution - Market Newsdesk","og_description":"Tekla Life Sciences Investors Paid Distribution BOSTON–(BUSINESS WIRE)– On March 31, 2023, Tekla Life Sciences Investors paid a distribution of $0.33 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $39,622,658, of which $31,823,721 represents net unrealized appreciation of portfolio securities. The following table sets forth the estimated amounts of the current distribution, paid on March 31, 2023, and the cumulative distributions paid this … Continue reading \"Tekla Life Sciences Investors Paid Distribution\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-31T13:58:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tekla Life Sciences Investors Paid Distribution","datePublished":"2023-03-31T13:58:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/"},"wordCount":669,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/","name":"Tekla Life Sciences Investors Paid Distribution - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-03-31T13:58:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230331005308r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tekla-life-sciences-investors-paid-distribution-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tekla Life Sciences Investors Paid Distribution"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=744319"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744319\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=744319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=744319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=744319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}